How many stocks are there of RemeGen Co?
The current number of stocks of RemeGen Co is 539.72 M undefined.
RemeGen Co Stocks 2024
RemeGen Co Stocks
539.72 M
Ticker
9995.HK
ISIN
CNE1000048G6
WKN
A2QGM4
In 2024, RemeGen Co had 539.72 M outstanding stocks, a 0% change from the 539.72 M stocks in the previous year.
The RemeGen Co Stocks history
| YEAR | NUMBER OF STOCKS (undefined CNY) |
|---|---|
| 2029e | 539.72 |
| 2028e | 539.72 |
| 2027e | 539.72 |
| 2026e | 539.72 |
| 2025e | 539.72 |
| 2024e | 539.72 |
| 2023 | 539.72 |
| 2022 | 531.29 |
| 2021 | 487.4 |
| 2020 | 408.1 |
| 2019 | 478.4 |
| 2018 | 478.4 |
RemeGen Co shares outstanding CNE1000048G6 · A2QGM4
The number of shares was RemeGen Co in 2023 — This indicates how many shares 539.725 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue RemeGen Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates RemeGen Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of RemeGen Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RemeGen Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2018 | 478.4 M Aktien |
| 2019 | 478.4 M Aktien |
| 2020 | 408.1 M Aktien |
| 2021 | 487.4 M Aktien |
| 2022 | 531.29 M Aktien |
| 2023 | 539.72 M Aktien |
| 2024e | 539.72 M Aktien |
| 2025e | 539.72 M Aktien |
| 2026e | 539.72 M Aktien |
| 2027e | 539.72 M Aktien |
| 2028e | 539.72 M Aktien |
| 2029e | 539.72 M Aktien |
RemeGen Co Aktienanalyse
What does RemeGen Co do?
RemeGen Co Ltd is a Chinese biotechnology company based in Yantai. The company was founded in 2008 by Dr. Li Zhu, who also developed the company's main product. RemeGen's goal is to develop innovative therapies for the treatment of cancer and autoimmune diseases. The company's business model involves researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. RemeGen works closely with leading researchers from around the world and conducts clinical trials to assess the safety and efficacy of its products. The company has various divisions focused on developing drugs for different diseases, including oncology, autoimmune diseases, and dermatology. RemeGen's flagship product is the antibody FGFR4, which is a new therapeutic agent for treating liver cancer. FGFR4 is one of the most highly expressed genes in liver cancer cells and plays a crucial role in tumor progression. The antibody inhibits the activity of FGFR4, thereby preventing the growth of liver cancer cells. Clinical studies have shown FGFR4 to be a promising treatment option for liver cancer, with positive results. In addition to FGFR4, RemeGen has other promising products in its development pipeline, including the antibody RC48, which is used in the treatment of advanced or metastatic lung cancer. RC48 targets the Epidermal Growth Factor Receptor (EGFR), a protein that is highly upregulated in many types of cancer and promotes the growth of cancer cells. Clinical studies have shown RC48 to be a promising treatment option for lung cancer, reaching Phase III. Overall, RemeGen Co Ltd has a promising approach to developing innovative drugs that have the potential to change the standard of care in oncology, autoimmune diseases, and dermatology. Through close collaboration with leading researchers and clinical trials, the company is well-positioned to further develop its pipeline and improve medical care for patients in China and worldwide. Answer: RemeGen Co Ltd is a Chinese biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. It has a business model of researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. The company's divisions focus on oncology, autoimmune diseases, and dermatology. Its flagship product is the antibody FGFR4, which is used for treating liver cancer. RemeGen also has other promising products, such as the antibody RC48 for advanced lung cancer. The company's approach has the potential to change the standard of care in these medical fields. RemeGen Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating RemeGen Co's Shares Outstanding
RemeGen Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in RemeGen Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding RemeGen Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in RemeGen Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about RemeGen Co stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of RemeGen Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of RemeGen Co evolved in recent years?
The number of shares of RemeGen Co has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. RemeGen Co as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of RemeGen Co?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does RemeGen Co pay?
Over the past 12 months, RemeGen Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RemeGen Co is expected to pay a dividend of 0 CNY.
What is the dividend yield of RemeGen Co?
The current dividend yield of RemeGen Co is .
When does RemeGen Co pay dividends?
RemeGen Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of RemeGen Co?
RemeGen Co paid dividends every year for the past 0 years.
What is the dividend of RemeGen Co?
For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.
In which sector is RemeGen Co located?
RemeGen Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von RemeGen Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of RemeGen Co from 12/17/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.
When did RemeGen Co pay the last dividend?
The last dividend was paid out on 12/17/2024.
What was the dividend of RemeGen Co in the year 2023?
In the year 2023, RemeGen Co distributed 0 CNY as dividends.
In which currency does RemeGen Co pay out the dividend?
The dividends of RemeGen Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von RemeGen Co
Our stock analysis for RemeGen Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RemeGen Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
